Vascular Biogenics Ltd (NASDAQ:VBLT) has been assigned an average rating of “Hold” from the six ratings firms that are covering the stock, MarketBeat reports. Four investment analysts have rated the stock with a hold recommendation and two have issued a buy recommendation on the company. The average 1 year price target among brokerages that have issued ratings on the stock in the last year is $2.94.
A number of equities research analysts recently commented on the company. HC Wainwright upgraded Vascular Biogenics from a “neutral” rating to a “buy” rating and set a $3.00 target price on the stock in a research report on Monday. Zacks Investment Research upgraded Vascular Biogenics from a “hold” rating to a “buy” rating and set a $1.75 target price on the stock in a research report on Thursday, August 23rd.
Shares of Vascular Biogenics stock opened at $1.44 on Friday. Vascular Biogenics has a 52 week low of $1.32 and a 52 week high of $9.05. The stock has a market capitalization of $48.67 million, a PE ratio of -3.89 and a beta of -1.86. The company has a current ratio of 10.45, a quick ratio of 10.45 and a debt-to-equity ratio of 0.01.
Vascular Biogenics Company Profile
Vascular Biogenics Ltd., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for cancer. The company's program is based on its proprietary vascular targeting system platform technology, which utilizes genetically targeted therapy to destroy newly formed or angiogenic blood vessels.
Featured Article: Treasury Bonds
Receive News & Ratings for Vascular Biogenics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vascular Biogenics and related companies with MarketBeat.com's FREE daily email newsletter.